Company profile

Anthony C. Hayes
Incorporated in
Fiscal year end
Former names
Biospherics Inc, Spherix Inc
IRS number

SPEX stock data


Investment data

Data from SEC filings
Securities sold
Number of investors


3 Feb 20
7 Apr 20
31 Dec 20


Company financial data Financial data

Quarter (USD) Dec 19 Sep 19 Jun 19 Mar 19
Net income 973K -3.36M -644K -1.15M
Diluted EPS -1.38 -0.3 -0.57
Operating income -3.18M -902K -888K -713K
Net change in cash -222K -251K 118K 429K
Cash on hand 91K 313K 564K 446K
Annual (USD) Dec 19 Dec 18 Dec 17 Dec 16
Revenue 9K 28K 1.24M 877K
Net income -4.18M 1.73M -3.31M -6.48M
Diluted EPS -1.67 0.91 -0.6 6.51
Net profit margin -46478% 6168% -267% -738%
Operating income -5.69M -6.87M -3.82M -8.55M
Net change in cash 74K -183K 100K 0
Cash on hand 91K 17K 200K 100K
Cost of revenue 9K 28K

Financial data from company earnings reports

Date Owner Security Transaction Code $Price #Shares $Value #Remaining
8 Nov 19 Aikido Pharma Common Stock Other Dispose J 0 9,226 0 1,636,230
28 Oct 19 Aikido Pharma Common Stock Other Dispose J 0 90,258 0 1,645,456
28 Feb 19 Aikido Pharma Common Stock Buy Aquire P 199998 35,714 7.14B 1,735,714
19 Nov 18 Tim S Ledwick Common Stock, $.0001 par value per share Grant Aquire A 0.9 10,000 9K 30,000
19 Nov 18 Anthony Hayes Common Stock, $.0001 par value per share Buy Aquire P 0.88 8,000 7.04K 52,183
19 Nov 18 Anthony Hayes Common Stock, $.0001 par value per share Buy Aquire P 0.9 2,000 1.8K 44,183
30 Jun 17 Aikido Pharma Common Stock Buy Aquire P 675000 1,700,000 1.15T 1,700,000
1.9% owned by funds/institutions
13F holders
Current Prev Q Change
Total holders 9 8 +12.5%
Opened positions 2 1 +100.0%
Closed positions 1 2 -50.0%
Increased positions 3 3
Reduced positions 0 1 -100.0%
13F shares
Current Prev Q Change
Total value 119K 136K -12.5%
Total shares 90.71K 81.35K +11.5%
Total puts 0 0
Total calls 0 0
Total put/call ratio
Largest owners
Shares Value Change
Renaissance Technologies 60.17K $79K +20.3%
Vanguard 20.74K $27K 0.0%
DB Deutsche Bank 2.27K $2K NEW
BAC Bank of America 538 $1K +2345.5%
Victory Capital Management 445 $1K +25.7%
BLK BlackRock 56 $0 0.0%
MS^L Morgan Stanley 1 $0 0.0%
Proequities 0 $0
Largest transactions
Shares Bought/sold Change
VIRT Virtu Financial 0 -10.15K EXIT
Renaissance Technologies 60.17K +10.14K +20.3%
UBS UBS 6.49K +6.49K NEW
DB Deutsche Bank 2.27K +2.27K NEW
BAC Bank of America 538 +516 +2345.5%
Victory Capital Management 445 +91 +25.7%
Vanguard 20.74K 0 0.0%
Proequities 0 0
MS^L Morgan Stanley 1 0 0.0%
BLK BlackRock 56 0 0.0%

Financial report summary

Management Discussion
  • The Company experienced very little or no revenue in the last two years and we don’t expect any revenue until a biotechnology product is fully developed which may not occur for many years.
  • For the year ended December 31, 2019 and 2018, we incurred a loss from operations of $5.7 million and $6.9 million, respectively. The decrease in net loss in the 2019 period was primarily attributed to $1.4 million decrease in amortization of patent portfolio, $2.2 million decrease in impairment of intangible assets, $0.2 million decrease in selling, general and administrative expense, and partially offset by $2.5 million increase in research and development expense related with license acquisition.
  • For the year ended December 31, 2019 and 2018, other expense (income) was approximately $1.5 million and $8.6 million, respectively. The decrease of other income was primarily attributed to a $6.8 million decrease in change in fair value of investments and a $0.7 million decrease in the fair value of warrant liabilities, and partially offset by $0.3 million decrease in other expenses. During the year ended December 31, 2019, we recorded a loss of $0.9 million related to our investment in DatChat and a $2.4 million unrealized loss on our investment in Hoth as the closing stock price Hoth increased from a cost basis of $5.42 to $6.19 as of December 31, 2019.
Content analysis ?
H.S. sophomore Avg
New words: abandon, ACA, academic, acral, acute, administered, advertising, altogether, AML, analogue, animal, antitumor, arbitration, art, Article, ATM, attain, Austin, billing, biological, BLA, broad, broaden, Budget, Cadillac, candidate, carefully, Carolina, cell, Center, centralized, certainty, Chapel, characterized, chemical, chemotherapeutic, chemotherapy, chose, chronically, clearance, CMS, complementary, complicating, concentrated, concentration, Congressional, constrain, contamination, convenience, convenient, convey, Cosmetic, Council, country, deadly, death, debilitating, decentralized, defraud, diagnostic, discovering, disease, disgorgement, domestically, double, earliest, ease, EC, effectuate, efficacy, enroll, enrolled, enrollment, environmental, EU, Europe, European, eventual, eventually, excise, expenditure, export, exposure, facility, false, FDC, FDCA, fewer, fire, Forest, formulation, fraudulent, gemcitabine, goal, halt, hazard, HCW, healthcare, hereof, Hill, hire, HIV, hope, immunity, immunodeficiency, immunogenic, immunotherapy, imposition, inconclusive, IND, ineffective, infrastructure, inhibiting, injury, insufficient, internationally, invite, IRB, jeopardize, Justice, justify, labeling, laboratory, led, leukemia, lifespan, local, lung, lymphoblastic, mandate, Master, Medicaid, medical, Medicare, medicinal, Medicine, melanoma, mice, milestone, MMA, Modernization, modestly, monetary, mouse, MSA, myeloid, NDA, nearest, newly, noncompliance, notably, nucleobase, oncology, orphan, overcome, oversee, pancreatic, Parliament, patient, payer, people, perspective, pharmacoeconomic, phospholipid, physician, pioneering, pipe, pipeline, poised, poolable, population, Portability, pose, potent, poverty, predetermined, preempted, prefunded, premarket, prescription, preserve, pressure, prevalence, prevalent, profile, promoting, promotion, promotional, prostate, protocol, prove, proximity, purity, quantity, radiation, rapidly, rare, rebate, recall, recordkeeping, recruiting, referral, refusal, regional, relapse, remuneration, renowned, repeal, repealed, repealing, repeated, replicate, resistance, resistant, restitution, revoked, safe, safer, safety, sample, satisfactorily, scheme, Serial, shorten, show, showed, showing, side, slower, sound, specialty, statute, stimulate, storage, strictly, strong, study, submission, Surprisingly, susceptible, suspension, sweeping, Taxpayer, therapeutic, therapy, tolerate, tolerated, toxicity, transgenic, transparency, tumor, turn, unacceptable, uncertificated, undesirable, unexpected, unfavorable, unmet, unpredictable, user, UT, UTA, violation, viral, VStock, Wainwright, warning, WF, withdrawal
Removed: abroad, accessible, alleged, allocating, antenna, Apple, appointed, ascribed, assumption, BCF, bifurcation, Blackberry, calendar, California, capacity, capitalized, cellular, challenge, circumstance, circumvented, classify, commencing, commitment, comparing, complex, comprised, computer, Conditionally, confirmatory, conjunction, consecutive, Consortium, controlled, court, curve, defending, defense, depreciation, detachable, detail, diligence, dismissal, district, employee, enable, equally, equipment, Equitable, Ericsson, extend, finite, flawed, frequency, functionality, furniture, hardware, inception, informing, infringed, instance, interference, intrinsic, introduced, invalid, inventor, iscurrently, launched, leader, letter, licensor, literature, LM, meaningful, Microsoft, midpoint, minimize, mobile, multiplied, narrowed, negotiated, Nortel, NY, obsolete, occurrence, offered, opposition, optical, optionee, originally, outlined, owed, patentable, periodic, previously, principally, publication, publicly, radio, ranging, recognizing, redemption, regain, regular, render, rental, Rockstar, RPX, satellite, seller, separation, settled, shifted, sixty, solar, Sony, station, sublicensing, technological, telecommunication, tested, underwriting, underwritten, undiscounted, uneconomical, unenforceable, Uniden, usage, valid, venture, video, voice, VTech, waived, withheld